Preceptor and Preceptee

PRECEPTOR

An experienced and competent professional

  • Acquire the necessary education and training
  • Act as a positive role model for the profession and demonstrates best practice and excellence in professional behaviours
  • Orientate and  integrate  the  preceptee  into  the  profession  and  the  clinical environment
  • Provide support and opportunity for learning
  • Respond to learner diversity and needs
  • Develop and maintain a respectful and inclusive environment
  • Instruct, supervise, assess and evaluate the preceptee
  • Provide and receive coaching and constructive feedback
  • Assist in the development of clinical skills
  • Assist in the transitioning of the preceptee from learner to practitioner who are reflective decision makers
  • Assist in the integration of theory with practice and consolidation of knowledge
  • Collaborate with preceptee at all stages of preceptorship

PRECEPTEE

  An active learner who is engaged in learning from a preceptor

  • Collaborate with preceptor at all stages of preceptorship
  • Take initiative, demonstrate motivation to learn and apply best practice principles
  • Be accountable and take responsibility for learning
  • Acquire and develop clinical skills
  • Integrate theory with practice and consolidate knowledge
  • Transition to a reflective decision maker
  • Integrate into the profession and clinical environment

Abortion

Ending of pregnancy, either spontaneous (miscarriage) or induced (termination of pregnancy) before 22 weeks LMP.

In countries where termination of pregnancy is legally restricted, induced abortions are often performed under poor conditions (non-sterile equipment, inappropriate equipment and/or substances, unqualified health care personnel, etc.). Complications (trauma, bleeding and severe infection) are common and may be life-threatening.

https://static.timesofisrael.com/atlantajewishtimes/uploads/2019/06/fetal-development.jpg

Diagnosis

Signs and symptoms

– Threatened abortion or missed abortion: light bleeding, abdominal pain, closed cervix.

– Incomplete abortion: more or less severe bleeding, abdominal pain, uterine contractions, expulsion of products of conception, open cervix.

– Trauma to the vagina or cervix or the presence of a foreign bodies are strongly suggestive of unsafe abortion. Look for complications, especially infection.

Additional investigations

– A pregnancy test is useful if the history and clinical examination are inconclusive.

– Ultrasound is useful for confirming failed pregnancy or the presence of retained products of conception after incomplete abortion.

Differential diagnosis

The main differential diagnoses are: ectopic pregnancy, cervicitis, ectropion (eversion of the cervical mucosa, which is more fragile and may bleed easily on contact, especially after a vaginal examination or sexual intercourse), cervical polyp, and functional uterine bleeding.

Management

Threatened abortion

– Advise the patient to reduce activity. Either the threat of abortion recedes, or abortion is inevitable.

– Look for a possible infectious cause (malaria or sexually transmitted infection) and treat it.

– Treat pain according to severity.

Missed abortion

If there are no signs of infection and/or no heavy bleeding, there is no urgency to perform uterine evacuation.

– Before 13 weeks LMP

Uterine evacuation can be performed by:

  • medication: misoprostol 600 micrograms sublingually or 800 micrograms vaginally (in the posterior fornix). Bleeding and cramping can be expected to start within 3 hours. If expulsion has not started within 3 hours, administer additional doses of misoprostol every 3 hours; max. 3 doses in total.

or

  • manual vacuum aspiration.

– Between 13 and 22 weeks LMP

mifepristone PO: 200 mg single dose, and 1 to 2 day later, misoprostol 400 micrograms sublingually

or intravaginally (into the posterior fornix), every 4 to 6 hours until labour starts, to be repeated if necessary the following day

or

misoprostol alone 400 micrograms sublingually or intravaginally (into the posterior fornix), every 4 to 6 hours until labour starts, to be repeated if necessary the following day

In case of 2 or more previous uterine scars or grand multiparity or overdistention of the uterus:

  • Preferably use the combined regimen mifepristone + misoprostol, as fewer numbers of misoprostol doses are required.
  • Reduce the dose of misoprostol to 200 micrograms every 6 hours.
  • Closely monitor the mother for possible signs of impending rupture (heart rate, blood pressure, uterine contractions, pain).

Ongoing or incomplete abortion without signs of infection

General measures

– Measure heart rate, blood pressure, temperature; assess severity of bleeding.

– In the event of heavy bleeding:

  • insert an IV line (16-18G catheter) and administer Ringer lactate;
  • closely monitor heart rate, blood pressure, bleeding;
  • prepare for a possible transfusion: determine the patient’s blood type, select potential donors or ensure that blood is available. If transfusion is necessary, only use blood that has been screened (HIV-1, HIV-2, hepatitis B, hepatitis C, syphilis, and malaria in endemic areas).

– Treat pain according to severity.

– Remove products of conception from the vagina and cervix, if present.

– Look for a cause (e.g. malaria or sexually transmitted infections) and treat it.

– Afterwards, provide iron + folic acid supplementation or, in the event of severe anaemia, a blood transfusion.

Uterine evacuation

– Before 13 weeks LMP

Uterine evacuation is usually required due to retained products of conception, which can cause bleeding and infection. There are 2 options:

  • Instrumental evacuation: manual vacuum aspiration or, if not available, instrumental curettage. Aspiration under local anaesthesia is the method of choice. It is technically easier to perform, less traumatic and less painful than curettage.
  • Medication: misoprostol 400 micrograms sublingually or 600 micrograms PO single dose

– Between 13 and 22 weeks LMP

  • Instrumental evacuation in case of haemorrhage: manual vacuum aspiration or instrumental curettage or digital curettage.
  • Medication: misoprostol 400 micrograms sublingually every 3 hours until expulsion. In the absence of expulsion after 3 additional doses, consider instrumental evacuation.

In case of 2 or more previous uterine scars or grand multiparity or overdistention of the uterus: same precautions as for missed abortion (see above).

Septic abortion

In the event of septic abortion (fever, abdominal pain, tender uterus, foul-smelling discharge), as above

AND:

– Remove foreign bodies from the vagina and cervix, if present; clean wounds.

– Perform uterine evacuation as soon as possible, irrespective of gestational age.

– Administer antibiotherapy as soon as possible:

amoxicillin/clavulanic acid IV (dose expressed in amoxicillin): 1 g every 8 hours + gentamicin IM: 5 mg/kg once daily

or

ampicillin IV: 2 g every 8 hours + metronidazole IV: 500 mg every 8 hours + gentamicin IM: 5 mg/kg once daily

Continue until the fever disappears (at least 48 hours), then change to:

amoxicillin/clavulanic acid PO (dose expressed in amoxicillin) to complete 5 days of treatment

Ratio 8:1: 3000 mg daily (= 2 tablets of 500/62.5 mg 3 times daily)

Ratio 7:1: 2625 mg daily (= 1 tablet of 875/125 mg 3 times daily)

or

amoxicillin PO: 1 g 3 times daily + metronidazole PO: 500 mg 3 times daily, to complete 5 days of treatment

For very severe infection (infected perforated uterus or peritonitis), treat for 10 days.

– Check and/or update tetanus immunisation (Table 2.1).

Table – Tetanus prophylaxis

Immunisation status Spontaneous abortion Unsafe abortion, with wound or foreign bodies
Not immunised
or
Immunisation status unknown
Begin immunisation against tetanus Begin immunisation against  tetanus
+
Human tetanus immune globulin
Incompletely immunised Tetanus booster Tetanus booster 
+
Human tetanus immune globulin
Fully immunised Last booster dose:
< 5 years No prophylaxis No prophylaxis
5 to 10 years No prophylaxis Tetanus booster
> 10 years Tetanus booster Tetanus booster
+
Human tetanus immune globulin

 

Boys and Puberty

Puberty is the time when you grow from a boy into a young man. Everyone goes through it. It can be exciting, but some people find it tough. Here’s what to expect.

How does my body change?
During puberty, your testicles (testes or ‘balls’) start producing the male hormone testosterone. This hormone triggers changes in your body. Suddenly you grow taller and begin to develop muscles. You will also find physical changes happening to your voice, your body hair and your genitals, and possibly even your breasts.

There are plenty of signs that puberty has started. Every boy is different, but here are some of the most common changes to look out for.

  • You grow taller, and you may become more muscular.
  • Your Adam’s apple (larynx) gets bigger and your voice deepens or begins to ‘break’.
    Your testicles begin to produce sperm.
  • Your body produces more hormones, so you might get erections when you least expect them.
  • Ejaculations can happen while you are asleep. These are called ‘nocturnal emissions’, or ‘wet dreams’. Wet dreams are totally normal.
  • You may get oily skin and hair, and spots (acne) may develop on your face and body.
    You may find you sweat more.
  • Hair will start to grow under your arms and around your penis and testicles. You may also find more hair growing on your legs and arms. Hair will also appear on your chin and upper lip.
  • You may have mood swings and feel emotional, but your feelings will settle down in time.
  • You may notice a swelling or lump under your nipples. This is normal and it will go away after a few months.

Girls and Puberty

What is puberty?
Puberty refers to the specific physical changes that happen as a child develops into an adult. Though they happen in different areas of the body, these changes are all related to each other.

Some of these changes include: bone growth; getting taller; making hormones in the adrenal glands and ovaries; growing pubic hair, underarm hair, and breasts; and the start of regular, monthly menstrual bleeding. Ultitmately puberty causes the girl to become fertile and release eggs regularly.

During puberty, the brain starts to send increasing signals to the ovaries and adrenal glands. In response, the ovaries make the hormones estrogen and progesterone. Adrenal glands make small amounts of the “male” hormones (androgens) that are made in females. These cause the breasts to grow, cause pubic and underarm hair to grow, and start the menstrual periods.

How does my body change?
Your body changes during puberty — you are going from being a child to how you will be when you are an adult.

During puberty, a lot of different things happen.

  • You’ll get taller, and this might happen quite quickly.
  • Your nipples may look swollen and feel tender. This is the start of your breasts growing, and usually happens between the ages of 8 to 13.
  • Your hips, bottom and thighs will probably get bigger and rounder.
  • Inside your body, your ovaries and womb will get larger.
  • Pubic hair will start growing around your vagina and under your arms. You may also find you have more hair on your legs. The hair will start off fine and straight, but become thicker and curlier.
  • Your clitoris will get larger.
  • Your first period, or menstruation, will probably arrive between the ages of 9 and 15 years. Every girl is different.
  • Your vagina will start to produce a small amount of clear or cream-coloured fluid (called vaginal discharge). This fluid, which keeps the walls of the vagina clean, is normal and healthy.
  • You may get oily skin and hair, and spots (acne) may develop on your face and body.
    You may also find you sweat more.
  • You may feel more emotional than usual and find you are sensitive to what others say.

These changes usually take place over about 4 years. By the time you are 16, you will have done most of your physical developing.

FACTS YOU DIDN’T KNOW ABOUT YOUR HYMEN

Surely on more than one occasion, you’ve heard about the supposed relationship between the hymen and a woman’s virginity. But this information is even faker than the love you swore to your ex 😉, since it really is just a myth that has been believed by women for years, and we’ll explain why here.

The first thing you need to know is that the hymen is a thin, elastic membrane located at the entrance of your vagina, which has a small hole that allows for menstrual flow each month and facilitates the placement of tampons, which, like any other part of our body, is different in every woman.

Does having a hymen means I’m a virgin?

Actually… They aren’t related! There are people who believe that if you’re a virgin the hymen is intact, but this is totally FALSE. A woman loses her virginity the moment she has sex with another person, that is when there’s intercourse. The hymen may or may not break during this activity due to its elasticity.

It’s important to know that there are women who are born with the hymen naturally open, or even without one, which is completely normal. There are also many activities that can break the hymen, such as biking, sports, or a hard fall. So you can’t really tell if someone has had sex by the way their hymen is. 

Learn to identify the myths and truths of your hymen with these 6 facts:

1. There are many shapes and sizes: as with the rest of our body, the hymen can vary in shape and size for each woman.

2. Some women don’t have one: there are many women who are born without a hymen but relax, it’s super normal!

3. It doesn’t always cause bleeding when you stretch: some women have hymens that stretch very easily and don’t cause bleeding. In fact, less than half of women experience some type of bleeding during their first sexual intercourse.

4. It isn’t something that can explode: it’s a false myth, the idea comes from the bleeding that some women have after having sex for the first time. The truth is that bleeding can happen when the hymen is stretched, not because it explodes.

5. It may hurt a little when it’s being stretched for the first time: it’s something that doesn’t happen to all women, but if it does, it’s a very small discomfort. 

6. It changes over time: in girls, the hymen is thick and bulky, but over time it becomes thinner and more fragile.

Remember that it’s really important to know our body in order to have better physical and sexual health. Before any strange change, it’s always better to visit your doctor

Chronic Obstructive Pulmonary Disease (COPD)

Key facts

  • Chronic obstructive pulmonary disease (COPD) is a progressive life-­threatening lung disease that causes breathlessness (initially with exertion) and predisposes to exacerbations and serious illness.
  • The Global Burden of Disease Study reports a prevalence of 251 million cases of COPD globally in 2016.
  • Globally, it is estimated that 3.17 million deaths were caused by the disease in 2015 (that is, 5% of all deaths globally in that year).
  • More than 90% of COPD deaths occur in low­ and middle-­income countries.
  • The primary cause of COPD is exposure to tobacco smoke (either active smoking or second­hand smoke).
  • Other risk factors include exposure to indoor and outdoor air pollution and occupational dusts and fumes.
  • Exposure to indoor air pollution can affect the unborn child and represent a risk factor for developing COPD later in life.
  • Some cases of COPD are due to long-term asthma.
  • COPD is likely to increase in coming years due to higher smoking prevalence and aging populations in many countries.
  • Many cases of COPD are preventable by avoidance or early cessation of smoking. Hence, it is important that countries adopt the WHO Framework Convention on Tobacco Control (WHO-FCTC) and implement the MPOWER package of measures so that non-smoking becomes the norm globally.
  • COPD is not curable, but treatment can relieve symptoms, improve quality of life and reduce the risk of death.

Chronic obstructive pulmonary disease (COPD) is a disease state characterized by airflow limitation that is not fully reversible. This newest definition of COPD, provided by the Global Initiative for Chronic Obstructive Lung Disease, provides a broad description that better explains this disorder and its signs and symptoms (National Institutes of Health [NIH], 2001).

Chronic obstructive pulmonary disease (COPD)

While previous definitions have included emphysema and chronic bronchitis under the umbrella classification of COPD, this was often confusing because most patients with COPD present with overlapping signs and symptoms of these two distinct disease processes.

 COPD may include diseases that cause airflow obstruction (eg, emphysema, chronic bronchitis) or a combination of these disorders. Other diseases such as cystic fibrosis, bronchiectasis, and asthma were previously classified as types of chronic obstructive lung disease. However, asthma is now considered a separate disorder and is classified as an abnormal airway condition characterized primarily by reversible inflammation. COPD can coexist with asthma. Both of these diseases have the same major symptoms; however, symptoms are generally more variable in asthma than in COPD.

People with COPD commonly become symptomatic during the middle adult years, and the incidence of COPD increases with age. Although certain aspects of lung function normally decrease with age (eg, vital capacity and forced expiratory volume in 1 second [FEV1]), COPD accentuates and accelerates these physiologic changes.

Pathophysiology

In COPD, the airflow limitation is both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases. The inflammatory response occurs throughout the airways, parenchyma, and pulmonary vasculature (NIH, 2001). Because of the chronic inflammation and the body’s attempts to repair it, narrowing occurs in the small peripheral airways. Over time, this injury-and-repair process causes scar tissue formation and narrowing of the airway lumen. Airflow obstruction may also be due to parenchymal destruction as seen with emphysema, a disease of the alveoli or gas exchange units.

In addition to inflammation, processes relating to imbalances of proteinases and antiproteinases in the lung may be responsible for airflow limitation. When activated by chronic inflammation, proteinases and other substances may be released, damaging the parenchyma of the lung. The parenchymal changes may also be consequences of inflammation, environmental, or genetic factors (eg, alpha1 antitrypsin deficiency).

Early in the course of COPD, the inflammatory response causes pulmonary vasculature changes that are characterized by thickening of the vessel wall. These changes may occur as a result of exposure to cigarette smoke or use of tobacco products or as a result of the release of inflammatory mediators (NIH, 2001).

Chronic Bronchitis

Chronic bronchitis, a disease of the airways, is defined as the presence of cough and sputum production for at least 3 months in each of 2 consecutive years. In many cases, smoke or other environmental pollutants irritate the airways, resulting in hypersecretion of mucus and inflammation. This constant irritation causes the mucus-secreting glands and goblet cells to increase in number, ciliary function is reduced, and more mucus is produced. The bronchial walls become thickened, the bronchial lumen is narrowed, and mucus may plug the airway. Alveoli adjacent to the bronchioles may become damaged and fibrosed, resulting in altered function of the alveolar macrophages. This is significant because the macrophages play an important role in destroying foreign particles, including bacteria. As a result, the patient becomes more susceptible to respiratory infection. A wide range of viral, bacterial, and mycoplasmal infections can produce acute episodes of bronchitis. Exacerbations of chronic bronchitis are most likely to occur during the winter.

Emphysema

In emphysema, impaired gas exchange (oxygen, carbon dioxide) results from destruction of the walls of overdistended alveoli. “Emphysema” is a pathological term that describes an abnormal distention of the air spaces beyond the terminal bronchioles, with destruction of the walls of the alveoli. It is the end stage of a process that has progressed slowly for many years. As the walls of the alveoli are destroyed (a process accelerated by recurrent infections), the alveolar surface area in direct contact with the pulmonary capillaries continually decreases, causing an increase in dead space (lung area where no gas exchange can occur) and impaired oxygen diffusion, which leads to hypoxemia. In the later stages of the disease, carbon dioxide elimination is impaired, resulting in increased carbon dioxide tension in arterial blood (hypercapnia) and causing respiratory acidosis. As the alveolar walls continue to break down, the pulmonary capillary bed is reduced.

Consequently, pulmonary blood flow is increased, forcing the right ventricle to maintain a higher blood pressure in the pulmonary artery. Hypoxemia may further increase pulmonary artery pressure. Thus, right-sided heart failure (cor pulmonale) is one of the complications of emphysema. Congestion, dependent edema, distended neck veins, or pain in the region of the liver suggests the development of cardiac failure.

Risk Factors for COPD

  • Exposure to tobacco smoke accounts for an estimated 80% to 90% of COPD cases (Rennard, 1998)
  • Passive smoking
  • Occupational exposure
  • Ambient air pollution
  • Genetic abnormalities, including a deficiency of alpha1-antitrypsin, an enzyme inhibitor that normally counteracts the destruction of lung tissue by certain other enzymes

Clinical Manifestations

COPD is characterized by three primary symptoms:

Katie Hrubec Hrubec Hrubec Burroughs @Megan Ward Ward Ward Anderson i guess i finally know what COPD is | Nursing school survival, Nursing mnemonics, Nurse

  • cough,
  • sputum production, and
  • dyspnea on exertion. These symptoms often worsen over time.
  • Chronic cough and sputum production often precede the development of airflow limitation by many years. However, not all individuals with cough and sputum production will develop COPD.
  • Dyspnea may be severe and often interferes with the patient’s activities.
  • Weight loss is common because dyspnea interferes with eating, and the work of breathing is energy-depleting.

Often the patient cannot participate in even mild exercise because of dyspnea; as COPD progresses, dyspnea occurs even at rest. As the work of breathing increases over time, the accessory muscles are recruited in an effort to breathe. The patient with COPD is at risk for respiratory insufficiency and respiratory infections, which in turn increase the risk for acute and chronic respiratory failure.

  • In COPD patients with a primary emphysematous component, chronic hyperinflation leads to the “barrel chest” thorax configuration. This results from fixation of the ribs in the inspiratory position (due to hyperinflation) and from loss of lung elasticity. Retraction of the supraclavicular fossae occurs on inspiration, causing the shoulders to heave upward. In advanced emphysema, the abdominal muscles also contract on inspiration.

Complications

There are two major life-threatening complications of COPD: respiratory insufficiency and failure.

  • Respiratory failure. The acuity and the onset of respiratory failure depend on baseline pulmonary function, pulse oximetry or arterial blood gas values, comorbid conditions, and the severity of other complications of COPD.
  • Respiratory insufficiency. This can be acute or chronic, and may necessitate ventilator support until other acute complications can be treated.

Assessment and Diagnostic Findings

Diagnosis and assessment of COPD must be done carefully since the three main symptoms are common among chronic pulmonary disorders.

  • Health history. The nurse should obtain a thorough health history from patients with known or potential COPD.
  • Pulmonary function studies. Pulmonary function studies are used to help confirm the diagnosis of COPD, determine disease severity, and monitor disease progression.
  • Spirometry. Spirometry is used to evaluate airway obstruction, which is determined by the ratio of FEV1 to forced vital capacity.
  • ABG. Arterial blood gas measurement is used to assess baseline oxygenation and gas exchange and is especially important in advanced COPD.
  • Chest x-ray. A chest x-ray may be obtained to exclude alternative diagnoses.
  • CT scan. Computed tomography chest scan may help in the differential diagnosis.
  • Screening for alpha1-antitrypsin deficiency. Screening can be performed for patients younger than 45 years old and for those with a strong family history of COPD.
  • Chest x-ray: May reveal hyperinflation of lungs, flattened diaphragm, increased retrosternal air space, decreased vascular markings/bullae (emphysema), increased bronchovascular markings (bronchitis), normal findings during periods of remission (asthma).
  • Pulmonary function tests: Done to determine cause of dyspnea, whether functional abnormality is obstructive or restrictive, to estimate degree of dysfunction and to evaluate effects of therapy, e.g., bronchodilators. Exercise pulmonary function studies may also be done to evaluate activity tolerance in those with known pulmonary impairment/progression of disease.
  • The forced expiratory volume over 1 second (FEV1): Reduced FEV1 not only is the standard way of assessing the clinical course and degree of reversibility in response to therapy, but also is an important predictor of prognosis.
  • Total lung capacity (TLC), functional residual capacity (FRC), and residual volume (RV): May be increased, indicating air-trapping. In obstructive lung disease, the RV will make up the greater portion of the TLC.
  • Arterial blood gases (ABGs): Determines degree and severity of disease process, e.g., most often Pao2is decreased, and Paco2 is normal or increased in chronic bronchitis and emphysema, but is often decreased in asthma; pH normal or acidotic, mild respiratory alkalosis secondary to hyperventilation (moderate emphysema or asthma).
  • DL CO test: Assesses diffusion in lungs. Carbon monoxide is used to measure gas diffusion across the alveocapillary membrane. Because carbon monoxide combines with hemoglobin 200 times more easily than oxygen, it easily affects the alveoli and small airways where gas exchange occurs. Emphysema is the only obstructive disease that causes diffusion dysfunction.
  • Bronchogram: Can show cylindrical dilation of bronchi on inspiration; bronchial collapse on forced expiration (emphysema); enlarged mucous ducts (bronchitis).
  • Lung scan: Perfusion/ventilation studies may be done to differentiate between the various pulmonary diseases. COPD is characterized by a mismatch of perfusion and ventilation (i.e., areas of abnormal ventilation in area of perfusion defect).
  • Complete blood count (CBC) and differential: Increased hemoglobin (advanced emphysema), increased eosinophils (asthma).
  • Blood chemistry: alpha1-antitrypsin is measured to verify deficiency and diagnosis of primary emphysema.
  • Sputum culture: Determines presence of infection, identifies pathogen.
  • Cytologic examination: Rules out underlying malignancy or allergic disorder.
  • Electrocardiogram (ECG): Right axis deviation, peaked P waves (severe asthma); atrial dysrhythmias (bronchitis), tall, peaked P waves in leads II, III, AVF (bronchitis, emphysema); vertical QRS axis (emphysema).
  • Exercise ECG, stress test: Helps in assessing degree of pulmonary dysfunction, evaluating effectiveness of bronchodilator therapy, planning/evaluating exercise program.

Medical Management

Healthcare providers perform medical management by considering the assessment data first and matching the appropriate intervention to the existing manifestation.

Pharmacologic Therapy

  • Bronchodilators. Bronchodilators relieve bronchospasm by altering the smooth muscle tone and reduce airway obstruction by allowing increased oxygen distribution throughout the lungs and improving alveolar ventilation.
  • Corticosteroids. A short trial course of oral corticosteroids may be prescribed for patients to determine whether pulmonary function improves and symptoms decrease.
  • Other medications. Other pharmacologic treatments that may be used in COPD include alpha1-antitrypsin augmentation therapy, antibiotic agents, mucolytic agents, antitussive agents, vasodilators, and narcotics.

Management of Exacerbations

  • Optimization of bronchodilator medications is first-line therapy and involves identifying the best medications or combinations of medications taken on a regular schedule for a specific patient.
  • Hospitalization. Indications for hospitalization for acute exacerbation of COPD include severe dyspnea that does not respond to initial therapy, confusion or lethargy, respiratory muscle fatigue, paradoxical chest wall movement, and peripheral edema.
  • Oxygen therapy. Upon arrival of the patient in the emergency room, supplemental oxygen therapy is administered and rapid assessment is performed to determine if the exacerbation is life-threatening.
  • Antibiotics. Antibiotics have been shown to be of some benefit to patients with increased dyspnea, increased sputum production, and increased sputum purulence.

Surgical Management

Patients with COPD also have options for surgery to improve their condition.

  • Bullectomy. Bullectomy is a surgical option for select patients with bullous emphysema and can help reduce dyspnea and improve lung function.
  • Lung Volume Reduction Surgery. Lung volume reduction surgery is a palliative surgery in patients with homogenous disease or disease that is focused in one area and not widespread throughout the lungs.
  • Lung Transplantation. Lung transplantation is a viable option for definitive surgical treatment of end-stage emphysema.

Nursing Management

Management of patients with COPD should be incorporated with teaching and improving the respiratory status of the patient.

Nursing Assessment

Assessment of the respiratory system should be done rapidly yet accurately.

  • Assess patient’s exposure to risk factors.
  • Assess the patient’s past and present medical history.
  • Assess the signs and symptoms of COPD and their severity.
  • Assess the patient’s knowledge of the disease.
  • Assess the patient’s vital signs.
  • Assess breath sounds and pattern.

Diagnosis

Diagnosis of COPD would mainly depend on the assessment data gathered by the healthcare team members.

  • Impaired gas exchange due to chronic inhalation of toxins.
  • Ineffective airway clearance related to bronchoconstriction, increased mucus production, ineffective cough, and other complications.
  • Ineffective breathing pattern related to shortness of breath, mucus, bronchoconstriction, and airway irritants.
  • Self-care deficit related to fatigue.
  • Activity intolerance related to hypoxemia and ineffective breathing patterns.

Planning & Goals

Goals to achieve in patients with COPD include:

  • Improvement in gas exchange.
  • Achievement of airway clearance.
  • Improvement in breathing pattern.
  • Independence in self-care activities.
  • Improvement in activity intolerance.
  • Ventilation/oxygenation adequate to meet self-care needs.
  • Nutritional intake meeting caloric needs.
  • Infection treated/prevented.
  • Disease process/prognosis and therapeutic regimen understood.
  • Plan in place to meet needs after discharge.

Nursing Priorities

  1. Maintain airway patency.
  2. Assist with measures to facilitate gas exchange.
  3. Enhance nutritional intake.
  4. Prevent complications, slow progression of condition.
  5. Provide information about disease process/prognosis and treatment regimen.

Nursing Interventions

Patient and family teaching is an important nursing intervention to enhance self-management in patients with any chronic pulmonary disorder.

To achieve airway clearance:

  • The nurse must appropriately administer bronchodilators and corticosteroids and become alert for potential side effects.
  • Direct or controlled coughing. The nurse instructs the patient in direct or controlled coughing, which is more effective and reduces fatigue associated with undirected forceful coughing.

To improve breathing pattern:

  • Inspiratory muscle training. This may help improve the breathing pattern.
  • Diaphragmatic breathing. Diaphragmatic breathing reduces respiratory rate, increases alveolar ventilation, and sometimes helps expel as much air as possible during expiration.
  • Pursed lip breathing. Pursed lip breathing helps slow expiration, prevents collapse of small airways, and control the rate and depth of respiration.

To improve activity intolerance:

  • Manage daily activities. Daily activities must be paced throughout the day and support devices can be also used to decrease energy expenditure.
  • Exercise training. Exercise training can help strengthen muscles of the upper and lower extremities and improve exercise tolerance and endurance.
  • Walking aids. Use of walking aids may be recommended to improve activity levels and ambulation.

To monitor and manage potential complications:

  • Monitor cognitive changes. The nurse should monitor for cognitive changes such as personality and behavior changes and memory impairment.
  • Monitor pulse oximetry values. Pulse oximetry values are used to assess the patient’s need for oxygen and administer supplemental oxygen as prescribed.
  • Prevent infection. The nurse should encourage the patient to be immunized against influenza and S. pneumonia because the patient is prone to respiratory infection.

Evaluation

During evaluation, the effectiveness of the care plan would be measured if goals were achieved in the end and the patient:

  • Identifies the hazards of cigarette smoking.
  • Identifies resources for smoking cessation.
  • Enrolls in smoking cessation program.
  • Minimizes or eliminates exposures.
  • Verbalizes the need for fluids.
  • Is free of infection.
  • Practices breathing techniques.
  • Performs activities with less shortness of breath.

Discharge and Home Care Guidelines

It is important for the nurse to assess the knowledge of patient and family members about self-care and the therapeutic regimen.

  • Setting goals. If the COPD is mild, the objectives of the treatment are to increase exercise tolerance and prevent further loss of pulmonary function, while if COPD is severe, these objectives are to preserve current pulmonary function and relieve symptoms as much as possible.
  • Temperature control. The nurse should instruct the patient to avoid extremes of heat and cold because heat increases the temperature and thereby raising oxygen requirements and high altitudes increase hypoxemia.
  • Activity moderation. The patient should adapt a lifestyle of moderate activity and should avoid emotional disturbances and stressful situations that might trigger a coughing episode.
  • Breathing retraining. The home care nurse must provide the education and breathing retraining necessary to optimize the patient’s functional status.

Documentation Guidelines

Documentation is an essential part of the patient’s chart because the interventions and medications given and done are reflected on this part.

  • Document assessment findings including respiratory rate, character of breath sounds; frequency, amount and appearance of secretions laboratory findings and mentation level.
  • Document conditions that interfere with oxygen supply.
  • Document plan of care and specific interventions.
  • Document liters of supplemental oxygen.
  • Document client’s responses to treatment, teaching, and actions performed.
  • Document teaching plan.
  • Document modifications to plan of care.
  • Document attainment or progress towards goals.

 

Cystic Fibrosis

Cystic fibrosis (CF) is the most common fatal autosomal recessive disease among the Caucasian population. An individual must inherit a defective copy of the CF gene (one from each parent) to have CF. Cystic fibrosis is usually diagnosed in infancy or early childhood, but patients may be diagnosed later in life. For individuals diagnosed later in life, respiratory symptoms are frequently the major manifestation of the disease.

Pathophysiology
This disease is caused by mutations in the CF transmembrane conductance regulator protein, which is a chloride channel found in all exocrine tissues. Chloride transport problems lead to thick, viscous secretions in the lungs, pancreas, liver, intestine, and reproductive tract as well as increased salt content in sweat gland secretions. In 1989, major breakthroughs were made in this disease with the identification of the CF gene. The ability to detect the common mutations of this gene allows for routine screening for this disease as well as the detection of carriers. Genetic counseling is an important part of health care for couples at risk.
Airflow obstruction is a key feature in the presentation of CF. This obstruction is due to bronchial plugging by purulent secretions, bronchial wall thickening due to inflammation, and, over time, airway destruction. These chronic retained secretions in the airways set up an excellent reservoir for continued bronchial infections.

 

 

 

 

 

 

 

Clinical Manifestations

The pulmonary manifestations of this disease include;

  • a productive cough, wheezing, hyperinflation of the lung fields on chest x-ray, and pulmonary function test results consistent with obstructive airways disease.
  • Colonization of the airways with pathogenic bacteria usually occurs early in life.
  • Staphylococcus aureus and Haemophilus influenzae are common organisms during early childhood. As the disease progresses, Pseudomonas aeruginosa is ultimately isolated from the sputum of most patients.
  • Upper respiratory manifestations of the disease include sinusitis and nasal polyps.

Nonpulmonary clinical manifestations include;

  • gastrointestinal problems (eg, pancreatic insufficiency, recurrent abdominal pain, biliary cirrhosis, vitamin deficiencies, recurrent pancreatitis, weight loss),
  • genitourinary problems (male and female infertility), and
  • Clubbing of the extremities.

Assessment and Diagnostic Findings

Most of the time, the diagnosis of CF is made based on an elevated result of a sweat chloride concentration test, along with clinical signs and symptoms consistent with the disease. Repeated sweat chloride values of greater than 60 mEq/L distinguish most individuals with CF from those with other obstructive diseases. A molecular diagnosis may also be used in evaluating common genetic mutations of the CF gene.

Medical Management
Pulmonary problems remain the leading cause of morbidity and mortality in CF. Because chronic bacterial infection of the airways occurs in individuals with CF, control of infections is key in the treatment.

  • Antibiotic medications are routinely prescribed for acute pulmonary exacerbations of the disease. Depending upon the severity of the exacerbation, aerosolized, oral, or intravenous antibiotic therapy may be used. Antibiotic agents are selected based upon the results of a sputum culture and sensitivity. Patients with CF have problems with bacteria that are resistant to multiple drugs and require multiple courses of antibiotic agents over long periods of time.
  • Bronchodilators are frequently administered to decrease airway obstruction. Differing pulmonary techniques are used to enhance secretion clearance. Examples include manual postural drainage and chest physical therapy, high-frequency chest wall oscillation, and other devices that assist in airway clearance (PEP masks [masks that generate positive expiratory pressure], “flutter devices” [devices that provide an oscillatory expiratory pressure pattern with positive expiratory pressure and assist with expectoration of secretions]).
  • Inhaled mucolytic agents such as dornase alfa (Pulmozyme) or N-acetylcysteine (Mucomyst) may also be used. These agents help to decrease the viscosity of the sputum and promote expectoration of secretions.
  • Anti-inflammatory: To decrease the inflammation and ongoing destruction of the airways, anti-inflammatory agents may also be used. These may include inhaled corticosteroids or systemic therapy. Other anti-inflammatory medications have also been studied in CF. Ibuprofen was studied in children with CF and some benefit was demonstrated, but there is little information on its use in young or older adults with CF.
  • Supplemental oxygen is used to treat the progressive hypoxemia that occurs with CF. It helps to correct the hypoxemia and may minimize the complications seen with chronic hypoxemia (pulmonary hypertension).
  • Lung transplantation is an option for a small, select population of CF patients. A double lung transplant technique is used due to the chronically infected state of the lungs seen in end-stage CF. Because there is a long waiting list for lung transplant recipients, many patients die while awaiting a transplant.
  • Gene therapy is a promising approach to management, with many clinical trials underway. It is hoped that various methods of administering gene therapy will carry healthy genes to the damaged cells and correct defective CF cells. Efforts are underway to develop innovative methods of delivering therapy to the CF cells of the airways.

Nursing Diagnosis
Based on the assessment data, the major nursing diagnoses are:

  • Ineffective airway clearance related to thick, tenacious mucus production.
  • Ineffective breathing pattern related to tracheobronchial obstruction.
  • Risk for infection related to bacterial growth medium provided by pulmonary mucus and impaired body defenses.
  • Imbalanced nutrition: less than body requirements related to impaired absorption of nutrients.
  • Anxiety related to hospitalization.
  • Compromised family coping related to child’s chronic illness and its demands on caregivers.
  • Deficient knowledge of the caregiver related to illness, treatment, and home care.

Nursing Management
Nursing care of the adult with CF includes assisting the patient to manage pulmonary symptoms and to prevent complications of CF.

  • Specific nursing measures include strategies that promote removal of pulmonary secretions; chest physiotherapy, including postural drainage, chest percussion, and vibration, and breathing exercises are implemented and are taught to the patient and to the family when the patient is very young.
  • The patient is taught the early signs and symptoms of respiratory infection and disease progression that indicate the need to notify the primary health care provider.
  • The nurse emphasizes the importance of an adequate fluid and dietary intake to promote removal of secretions and to ensure an adequate nutritional status. Because CF is a life-long disorder, patients often have learned to modify their daily activities to accommodate their symptoms and treatment modalities.
  • Although gene therapy and double lung transplantation are promising therapies for CF, they are limited in availability and largely experimental. As a result, the life expectancy of adults with CF is shortened.
  • For the patient whose disease is progressing and who is developing increasing hypoxemia, preferences for end-of-life care should be discussed, documented, and honored.
  • Patients and family members need support as they face a shortened life span and an uncertain future.

 

Asthma

Asthma is a chronic inflammatory disorder of the airways associated with airway hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness and coughing. These episodes are usually associated with airflow obstruction within the lung, often reversible, either spontaneously or with treatment.

Factors that precipitate/aggravate asthma include: allergens, infection, exercise, drugs (aspirin), tobacco, etc.

Pathophysiology:-

Airway inflammation is the primary problem in asthma. An initial event in asthma appears to be the release of inflammatory mediators triggered. The mediators are released from bronchial mast cells, alveolar macrophages, and epithelial cells. Some mediators directly cause acute bronchoconstriction.” The inflammatory mediators also direct the activation of eosinophils and neutrophils, and their migration to the airways, where they cause injury Called “late-phase asthmatic response” results in epithelial damage, airway edema, mucus hypersecretion and hyper responsiveness of bronchial smooth muscle varying airflow obstruction leads to recurrent episodes of wheezing, breathlessness, chest tightness and cough.

Asthma Pathophysiology airway diagram

info-graphic about Severe Asthma Pathophysiology, Healthy airway and what is severe asthma

Causes/Triggers of Asthma:

The exact causes of asthma are still unknown but we do know that children are more likely to have asthma if other members of the family also have it. Related conditions like hay fever, eczema or food allergies can also increase the risk of asthma.

Asthma Triggers Smoking during pregnancy or exposing a child to tobacco smoke will increase their risk of developing asthma. Being overweight also increases the risk of developing asthma.

Though some children lose their symptoms as they grow older, asthma is a chronic disease so symptoms may come back later in life.

  • Asthma is a breathing disease which is triggered by various allergies and substance, like:
    • polluted matters, smoking, animal products and many more.
  • Asthma problems can be caused by different foods which can react on the immune system of the body. Some people have allergy with particular food and various symptoms are appeared in your body like swelling, vomiting, diarrhea, rash, wheezing and breathing problems. The use of foods like peanuts, shellfish, eggs, various dairy products can be harmful for the patients so they should avoid all these foods. All such foods and wine containing histamine can cause development in asthma.
  • The fizzy drinks, prepared salads and meats, home brewed beer and wine can contain the allergic reaction. If you have some problems of allergy, then you should contact with specialist for the allergic problems. The women can face the asthma problems during their periods, pregnancy, puberty and menopause.

The following things can trigger an asthma attack:

  • Colds and Viral Infections
  • House Dust Mites
  • Fur and dander from pets
  • Changes in weather, and cold air
  • Pollen
  • Tobacco smoke and pollution
  • Mould
  • Chemicals
  • Allergies
  • Exercise

Clinical Manifestations

The three most common symptoms of asthma are cough, dyspnea, and wheezing. In some instances, cough may be the only symptom. Asthma attacks often occur at night or early in the morning, possibly due to circadian variations that influence airway receptor thresholds.

  • Cough. There are instances that cough is the only symptom.
  • Dyspnea. General tightness may occur which leads to dyspnea.
  • Wheezing. There may be wheezing, first on expiration, and then possibly during inspiration as well.
  • Asthma attacks frequently occur at night or in the early morning.
  • An asthma exacerbation is frequently preceded by increasing symptoms over days, but it may begin abruptly.
  • Expiration requires effort and becomes prolonged.
  • As exacerbation progresses, central cyanosis secondary to severe hypoxia may occur.
  • Additional symptoms, such as diaphoresis, tachycardia, and a widened pulse pressure, may occur.
  • Exercise-induced asthma: maximal symptoms during exercise, absence of nocturnal symptoms, and sometimes only a description of a “choking” sensation during exercise.
  • A severe, continuous reaction, status asthmaticus, may occur. It is life-threatening.
  • Eczema, rashes, and temporary edema are allergic reactions that may be noted with asthma.

Assessment of the severity of asthma attack

  • The severity of the asthma attack must be rapidly evaluated by the following clinical criteria. Not all signs are necessarily present.

Assessment of severity in children over 2 years and adults

Mild to moderate attack Severe attack Life threatening attack
to talk in sentences

Respiratory rate (RR)
Children 2-5 years ≤ 40/ minute

Children > 5 years ≤ 30/ minute

Heart rate

Children 2-5 years ≤ 140/ minute
Children > 5 years ≤ 125/ minute
and
No criteria of severity

Cannot complete sentences in one breath
or
Too breathless to talk or feed

RR

Children 2-5 years > 40/minute
Children > 5 years > 30/minute
Adults ≥ 25/minute

Heart rate
Children 2-5 years > 140/minute
Children > 5 years > 125/minute
Adults ≥ 110/minute

SpO2 ≥ 92%

Altered level of consciousness
(drowsiness, confusion, coma)

Exhaustion
Silent chest
Paradoxical thoracoabdominal movement
Cyanosis
Collapse
Bradycardia in children or arrhythmia/ hypotension in adults

 

 

SpO2 < 92%

Assessment and Diagnostic Findings

A complete family, environmental, and occupational history is essential.

  • Positive family history. Asthma is a hereditary disease, and can be possibly acquired by any member of the family who has asthma within their clan.

  • Environmental factors. Seasonal changes, high pollen counts, mold, pet dander, climate changes, and air pollution are primarily associated with asthma.
  • Comorbid conditions. Comorbid conditions that may accompany asthma may include gastroeasophageal reflux, drug-induced asthma, and allergic broncopulmonary aspergillosis.

Complications

Complications of asthma may include status asthmaticus, respiratoryfailure, pneumonia, and atelectasis. Airway obstruction, particularly during acute asthmatic episodes, often results in hypoxemia, requiring the administration of oxygen and the monitoring of pulse oximetry and arterial blood gases. Fluids are administered because people with asthma are frequently dehydrated from diaphoresis and insensible fluid loss with hyperventilation.

Medical Management

Immediate intervention is necessary because the continuing and progressive dyspnea leads to increased anxiety, aggravating the situation.

Goals of Asthma Therapy

  • Prevent recurrent exacerbations and minimize the need for emergency department visits or hospitalizations
  • Maintain (near‐) “normal” pulmonary function
  • Maintain normal activity levels (including exercise and other physical activity)
  • Provide optimal pharmacotherapy with minimal or no adverse effects

Pharmacologic Therapy

There are two classes of medications—long-acting control and quick-relief medications—as well as combination products.

  • Short-acting beta2-adrenergic agonists
  • Anticholinergics
  • •Corticosteroids: metered-dose inhaler (MDI)
  • Leukotriene modifiers inhibitors/antileukotrienes
  • Methylxanthines

Mild to moderate attack

– Reassure the patient; place him in a 1/2 sitting position.
– Administer:

• salbutamol (aerosol): 2 to 4 puffs every 20 to 30 minutes, up to 10 puffs if necessary during the first hour. In children, use a spacer 1to ease administration (use face mask in children under 3 years).
Single puffs should be given one at a time, let the child breathe 4 to 5 times from the spacer before repeating the procedure.

• prednisolone PO: one dose of 1 to 2 mg/kg
– If the attack is completely resolved: observe the patient for 1 hour (4 hours if he lives far from the health centre) then give outpatient treatment: salbutamol for 24 to 48 hours (2 to 4 puffs every 4 to 6 hours depending on clinical evolution) and prednisolone PO (1 to 2 mg/kg once daily) to complete 3 days of treatment.
– If the attack is only partially resolved, continue with salbutamol 2 to 4 puffs every 3 to 4 hours if the attack is mild; 6 puffs every 1 to 2 hours if the attack is moderate, until symptoms subside, then when the attack is completely resolved, proceed as above.
– If symptoms worsen or do not improve, treat as sever attack.

Severe attack
– Hospitalise the patient; place him in a 1/2 sitting position.
– Administer:
• oxygen continuously, at least 5 litres/minute or maintain the SpO2 between 94 and 98%.
• salbutamol (aerosol): 2 to 4 puffs every 20 to 30 minutes, up to 10 puffs if necessary in children under 5 years, up to 20 puffs in children over 5 years and adults. Use a spacer to increase effectiveness, irrespective of age.

or salbutamol (solution for nebulisation), see Life-threatening attack
• prednisolone PO: one dose of 1 to 2 mg/kg
In the case of vomiting, until the patient can tolerate oral prednisolone, use hydrocortisone IV:
Children 1 month to < 5 years: 4 mg/kg every 6 hours (max. 100 mg per dose)
Children 5 years and over and adults: 100 mg every 6 hours
– If the attack is completely resolved, observe the patient for at least 4 hours. Continue the treatment with salbutamol for 24 to 48 hours (2 to 4 puffs every 4 hours) and prednisolone PO (1 to 2 mg/kg once daily) to complete 3 days of treatment.

Reassess after 10 days: consider long-term treatment if the asthma attacks have been occurring for several months. If the patient is already receiving long-term treatment, reassess the severity of the asthma (see table) and review compliance and correct use of medication and adjust treatment if necessary.
– If symptoms worsen or do not improve, see Life-threatening attack.

Life-threatening attack (intensive care)
– Insert an IV line.
– Administer:
• oxygen continuously, at least 5 litres/minute or maintain the SpO2 between 94 and 98%.
• salbutamol + ipratropium nebuliser solutions using a nebuliser:

 

Children 1 month to < 5 years salbutamol 2.5 mg + ipratropium 0.25 mg every 20 to 30 minutes
Children 5 to < 12 years salbutamol 2.5 to 5 mg + ipratropium 0.25 mg every 20 to 30  minutes
Children 12 years and over and adults salbutamol 5 mg + ipratropium 0.5 mg every 20 to 30 minutes

The two solutions can be mixed in the nebuliser reservoir.

corticosteriods (prednisolone PO or hydrocortisone IV) as for severe attack
– If the attack is resolved after one hour: switch to salbutamol aerosol and continue prednisolone PO as for severe attack
– If symptoms do not improve after one hour:

administer a single dose of magnesium sulfate by IV infusion in 0.9% sodium chloride over 20 minutes, monitoring blood pressure:

Children over 2 years: 40 mg/kg

Adults: 1 to 2 g

continue salbutamol by nebulisation and corticosteriods, as above.

Notes:

– In pregnant women, treatment is the same as for adults. In mild or moderate asthma attacks, administering oxygen reduces the risk of foetal hypoxia.

– For all patients, irrespective of the severity of the asthma attack, look for underlying lung infection and treat accordingly.

If a conventional spacer is not available, use a 500 ml plastic bottle: insert the mouthpiece of the inhaler into a hole made in the bottom of the bottle (the seal should be as tight as possible). The child breathes from the mouth of the bottle in the same way as he would with a spacer. The use of a plastic cup instead of a spacer is not recommended (ineffective).

Nursing Management

The immediate nursing care of patients with asthma depends on the severity of symptoms. The patient and family are often frightened and anxious because of the patient’s dyspnea.
Therefore, a calm approach is an important aspect of care.

  • Assess the patient’s respiratory status by monitoring the severity of symptoms, breath sounds, peak flow, pulse oximetry, and vital signs.
  • Obtain a history of allergic reactions to medications before administering medications.
  • Identify medications the patient is currently taking.
  • Administer medications as prescribed and monitor the patient’s responses to those medications; medications may include an antibiotic if the patient has an underlying respiratory infection.
  • Administer fluids if the patient is dehydrated.
  • Assist with intubation procedure, if required.

Promoting Home- and Community-Based Care

Teaching Patients Self-Care

  • Teach patient and family about asthma (chronic inflammatory), purpose and action of medications, triggers to avoid and how to do so, and proper inhalation technique.
  • Instruct patient and family about peak-flow monitoring.
  • Teach patient how to implement an action plan and how and when to seek assistance.
  • Obtain current educational materials for the patient based on the patient’s diagnosis, causative factors, educational level, and cultural background.

Continuing Care

  • Emphasize adherence to prescribed therapy, preventive measures, and need for follow-up appointments.
  • Refer for home health nurse as indicated.
  • Home visit to assess for allergens may be indicated (with recurrent exacerbations).
  • Refer patient to community support groups.
  • Remind patients and families about the importance of health promotion strategies and recommended health screening.